Arizona Tribune - Hypha Labs Provides Shareholder Update

Greetings,

While we have been quiet of late we have not been idle, and I am pleased to offer this brief update for your consideration. When you are at the helm of a Company which I firmly believe will soon transform an industry there are many, many moving pieces to consider, both within our revolutionary device and the market in front of us.

I am pleased and optimistic about what I see inside our laboratory and beyond our doors.

Our team continues to persevere to perfect our patent-pending Mushroom Accelerator which allows for a splendid crop of mushrooms to be cultivated on a kitchen counter in about eight days. Because you get only one first impression, our engineers are constantly testing, innovating, and evaluating so that when we go-to-market we do so with our best. Expect more communication about all this very, very soon.

And as we endeavor in our white coats ever mindful of the opportunity, we see that opportunity expanding perhaps exponentially. Recent events now align to some extent government and public views in favor of the magic of the mushroom.

These are no small movements.

Recent developments across the United States signal growing momentum for psilocybin legalization and therapeutic use. In April 2025, New Mexico became the third state to legalize medical psilocybin, joining Oregon and Colorado. The new law targets treatment-resistant conditions such as PTSD, depression, and end-of-life anxiety, and establishes a regulatory advisory board to oversee implementation. Meanwhile, the Iowa House passed a similar medical psilocybin bill, which now moves to the Senate for further debate. Colorado also made headlines this spring by issuing its first psilocybin therapy training credits and preparing to launch a statewide licensing program for healing centers by year's end.

At the federal level, President Trump's nominee for U.S. Surgeon General, Dr. Casey Means, has publicly praised guided psilocybin therapy, citing both clinical benefits and personal experience. Several U.S. cities-including Tacoma, Washington-have also moved to decriminalize natural psychedelics in recent months. Meanwhile, public interest continues to rise, with studies showing that adult use of psilocybin has doubled since 2019. As legal frameworks expand and public acceptance grows, these milestones reflect a transformative moment for mental health care and the future of psychedelic therapeutics.

We intend to be ready and able to support any potential regulatory changes that could usher a massive shift in the way consumers obtain all functional mushrooms. The existing functional mushroom market as it stands ($33 billion 2025, $62 billion projected 2032) is already an incredible opportunity for a Company with disruptive technology like ours. A deregulated approach to the magic of the mushroom could be exponentially more lucrative.

Sincerely,

Stone Douglass

Chief Executive Officer

About Hypha Labs, Inc.

The company has developed revolutionary, cutting-edge technology focused on new methods of producing the active ingredients found in a wide array of functional mushrooms using its patent-pending mushroom accelerators. The Company is positioning itself to play an important role in the burgeoning Functional Mushroom industry in addition to being a disruptive force in future and emerging mushroom opportunities. Visit us at HyphaLabs.com.

SAFE HARBOR FORWARD LOOKING STATEMENTS:

This press release may contain forward looking statements that are based on current expectations, forecasts, and assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected, including statements related to the amount and timing of expected revenues related to our financial performance, expected revenue, contracts, and future growth for upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC) and on the OTC Disclosure & News Service (OTCDNS). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in our filings with the SEC and/or OTCDNS. Among other matters, the Company may not be able to sustain growth or achieve profitability based upon many factors including but not limited to the risk that we will not be able to find and secure construction contracts and the necessary assets that will enable us to become profitable. Reference is hereby made to cautionary statements set forth in the Company's most recent SEC and/or OTCDNS filings. We have incurred and will continue to incur significant expenses in our development stage, noting that there is no assurance that we will generate enough revenues to offset those costs in both the near and long term. New lines of business in the construction industry may expose us to additional legal and regulatory costs and unknown exposure(s), the impact of which cannot be predicted at this time. Words such as "estimate," "project," "predict," "will," "would," "should," "could," "may," "might," "anticipate," "plan," "intend," "believe," "expect," "aim," "goal," "target," "objective," "likely" or similar expressions that convey the prospective nature of events or outcomes generally indicate forward-looking statements. You should not place undue reliance on these forward-looking statements, which speak only as of this press release. Unless legally required, we undertake no obligation to update, modify or withdraw any forward-looking statements, because of new information, future events or otherwise.

From time to time, the Company may post new and material information on its website or through its social media profiles at the links below:

LN: https://www.linkedin.com/company/hypha-labs-inc/
FB: https://www.facebook.com/hyphalabs
IG: https://www.instagram.com/hyphalabsinc/

Twitter: https://x.com/Hypha_Labs

For more information about Hypha Labs visit HyphaLabs.com

For the Company's current Investor Presentation please visit www.HyphaLabs.com/deck

Investor and Media Relations:

Integrity MediaInc.
(888) 216-3595
[email protected]

SOURCE: Hypha Labs, Inc.

View the original press release on ACCESS Newswire

M.Robinson--AT